The testing solutions for the detection of SARS-CoV-2

DiaSorin strives to improve health-care around the globe through the development of innovative diagnostic solutions that can lead to better patient outcomes and provide economic benefits to the healthcare system. Thanks to its team of dedicated scientists DiaSorin has been able to promptly deliver diagnostic solutions to manage the COVID-19 pandemic emergency.

DiaSorin provides diagnostic laboratories with solutions that include detection of SARS-CoV-2 Ag, antibodies determination and molecular testing:

A high-quality tool to verify immune responses of vaccinated individuals

DiaSorin is supporting Public Health Systems confirm the efficacy of their vaccination strategy with a cost-effective, automated, high-throughput SARS-CoV-2 serology testing solution.

• The LIAISON^® SARS-CoV-2 TrimericS IgG assay enables the reliable detection of Trimeric S spike protein IgG antibodies – the body’s natural defense response against SARS-CoV-2.
• The LIAISON^® SARS-CoV-2 TrimericS IgG assay is able to identify patients diagnosed for COVID-19 by virus variants (Lineage B.1.1.7 and Lineage P.1)
• The solution was used to evaluate pre- and post-vaccination samples to support the Italian national vaccine program at a hospital in Alessandria (Italy)
• A total of 102 sets of samples were collected from apparently healthy adults that were SARS-CoV-2 IgG negative at the time of vaccine and who received the full course (2 injections) of the Pfizer vaccine, COMIRNATY^® 
• The LIAISON^® SARS-CoV-2 TrimericS IgG was able to verify the effectiveness of the vaccine with a sensitivity of 99% (21 days after the first injection) and 100% (21 days after the second injection).